Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more
All eyes were on Lyft (LYFT) as it priced its IPO, along with two biotechs, Genfit (GNFT) and Precision BioSciences (DTIL), in a week that saw positive IPO returns across the board. ...read more
Genfit, a Phase 3 French biotech developing therapies for NASH, raised $135 million by offering 6.65 million ADSs at $20.32 per ADS. It had previously filed to raise $132 million by offering 5.0 million ADSs at $26.33. Genfit plans to list on the Nasdaq under...read more
The long-awaited IPO of rideshare giant Lyft (LYFT) will finally hit the market in the week ahead. In total, three IPOs plan to raise roughly $2.3 Billion in the IPO market, a further signal of an IPO market continuing to heat up after roughly...read more
NASHville: 89bio is the latest biotech IPO targeting liver disease NASH
Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more
US IPO Weekly Recap: Lyft makes its debut
All eyes were on Lyft (LYFT) as it priced its IPO, along with two biotechs, Genfit (GNFT) and Precision BioSciences (DTIL), in a week that saw positive IPO returns across the board. ...read more
Paris-listed NASH biotech Genfit prices US IPO at $20.32
Genfit, a Phase 3 French biotech developing therapies for NASH, raised $135 million by offering 6.65 million ADSs at $20.32 per ADS. It had previously filed to raise $132 million by offering 5.0 million ADSs at $26.33. Genfit plans to list on the Nasdaq under...read more
US IPO Week Ahead: Houston we have Lyft off
The long-awaited IPO of rideshare giant Lyft (LYFT) will finally hit the market in the week ahead. In total, three IPOs plan to raise roughly $2.3 Billion in the IPO market, a further signal of an IPO market continuing to heat up after roughly...read more